Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Dementia Clinical Trial

Official title:

Higher Neural and Cognitive Changes Following Anticholinergic Versus Beta 3 Agonist Versus Placebo Treatments in Female Patients With Overactive Bladder: a Multicenter Randomized Controlled Pilot Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03817931
• Other study ID #: 160362
• Status: Completed
• Phase: Phase 4
• Start date: August 5, 2019
• Est. completion date: February 26, 2022

Study information

• Verified date: August 2019
• Source: Baylor Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.

Description:

Women presenting to the urology clinic with complaints of urinary urgency, frequency in the absence of urinary tract infection or other obvious pathology will be screened for inclusion/exclusion criteria. Qualifying subjects will be consented. Baseline health information, bladder symptom questionnaires (Overactive Bladder-questionnaire(OABq), Patient Perception of Bladder Condition (PPBC)), Personal Health Questionnaire-9 (PHQ-9),Hamilton Anxiety Rating Scale (HAM-A), Montreal cognitive assessment (MoCA) will be given. If baseline depression (PHQ-9 score 15 or greater),dementia (MoCA score 25 or less), anxiety (HAM-A score 25-30) are noted the subject is excluded. 15 patients will be recruited from Baylor Scott & White Health Urology clinic, and 15 patients will be recruited from Houston Methodist Urology clinic. They will schedule a date within 1 month for the Rey Auditory Verbal Learning Test (RAVLT) and brain functional MRI (fMRI). RAVLT test is performed, followed by resting state fMRI and memory task during fMRI. Vials of medication will be distributed. Vials will be labeled 1-30 and will contain 30 tablets each. The anticholinergic and beta-3 agonist tablets will be encapsulated to look identical to the placebo tablet. Subjects will be reimbursed at this visit. fMRI images at baseline and post-intervention will be analyzed by a radiologist for incidental findings. One week and two weeks after initiating their tablets, phone interviews will inquire about pill count, side effects, and any new medications. Follow up testing date will be scheduled during the call. The same questions will be repeated at completion of the tablets (30 days after initiation). At completion of the tablets, subjects return to Houston Methodist for repeat RAVLT and fMRI. Subjects will be reimbursed the other half of their compensation at this visit. An expert physicist will analyze the BOLD signal intensity and FC pattern in a priori selected regions of interest before and after interventions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: February 26, 2022
• Est. primary completion date: February 2, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Female patients of age 50 to 90 years old with OAB as defined by the International Continence Society (Urgency with or without urge incontinence, usually with frequency and nocturia in the absence of urinary tract infection or other obvious pathology) who report that symptoms cause moderate problems using the PPBC.
• English-speaking and able to consent

Exclusion Criteria:

• Males are excluded to eliminate prostate pathology and urethral strictures, as well as possible bias of gender differences on fMRI.
• Subjects with moderately severe or severe depression (screening score of 15 or more) on the Personal Health Questionnaire-9 (PHQ-9)
• Subjects with moderate to severe anxiety (screening score 25-30) on the Hamilton Anxiety Rating Scale (HAM-A)
• A screening score indicating below normal cognitive function at baseline (score of 25 or less) on the montreal cognitive assessment.
• Subjects with neurologic disorders, dementia, prior cerebrovascular accident, neurogenic bladder or post-void residual greater than 250 mL
• Anticholinergics for OAB or beta 3 agonists use for treatment of OAB in the preceding six months prior to enrollment
• Pregnant or planning to become pregnant in the next six months, or current breastfeeding
• The inability to undergo MRI

Related Conditions & MeSH terms

• Dementia
• Incontinence, Urge
• Lower Urinary Tract Symptoms
• Overactive Bladder
• Urinary Bladder, Overactive
• Urinary Incontinence, Urge

Intervention

Drug:
• Anticholinergic
Tablet taken once daily.
• Beta-3 Agonists, Adrenergic
Tablet taken once daily.

Diagnostic Test:
• Functional magnetic resonance imaging (fMRI)
All subjects have fMRI at baseline and again after 30 days
• Rey Auditory Verbal Learning Test (RAVLT)
All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.

Locations

Country	Name	City	State
United States	Houston Methodist Hospital	Houston	Texas
United States	Baylor Scott and White Health	Temple	Texas

Sponsors (3)

Lead Sponsor	Collaborator
Baylor Research Institute	International Urogynecological Association, The Methodist Hospital Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Functional connectivity on MRI	Functional connectivity during a word recognition task will be compared within subjects from baseline and after 29+/- 1 day of intervention medication.	29 +/-1 days
Primary	Resting state blood oxygenation level dependent (BOLD)changes	During resting state, BOLD changes will be compared within subjects from baseline and after 29+/- 1 day of intervention medication.	29 +/-1 days
Primary	Diffusion tensor imaging	Fractional anisotropy and mean diffusivity from diffusion tensor images will be compared within subjects from baseline and after 29+/- 1 day of intervention medication.	29 +/-1 days
Secondary	Score on Rey Auditory Verbal Learning Test (RAVLT)	Baseline testing will be compared with post-intervention testing	30 days
Secondary	Overactive bladder questionnaire (OAB-q)	Baseline score of this validated questionnaire will be compared with post-intervention score	30 days
Secondary	Patient Perception of Bladder Condition (PPBC)	Baseline score of this validated questionnaire will be compared with post-intervention score	30 days

External Links

•   Houston Methodist Translational Imaging Center